title: ATM sequences from U2OS cells treated with evolved  L3-2 TALENs
design: Sequencing from Hubbard et al, 2015.  U2OS cells were nucleofected with a plasmid expressing heterodimeric FokI fusions to evolved L3-2 TALEs, together with a plasmid encoding the canonical ATM-R TALE–FokI fusion protein. After 48 h, genomic DNA was harvested and the ATM target site and its corresponding known off-target sites OffA11 and OffA17 were amplified from this genomic DNA.  The amplified sites were then high-throughput sequenced.  All genomic target sites (ATM on-target, OffA11 and OffA17) were combined together for this one type of treatment with L3-2 TALENs